Dr. Anna Lisa Alperovich, MD

Dr. Alperovich practices at NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital.

Dr. Alperovich's NPI, 1124388269, was assigned on May 23, 2012. Dr. Alperovich graduated from St. George's University School of Medicine in 2012. Dr. Alperovich holds New York license 280809.

Dr. Alperovich's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center, at 525 East 68th Street, New York, NY 10065 in New York County. The practice phone is (212) 746-5454.

Dr. Alperovich's primary practice is NewYork-Presbyterian/Weill Cornell Medical Center in New York, New York, part of NewYork-Presbyterian Hospital. Dr. Alperovich is also affiliated with Westchester Medical Center. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Alperovich to 11 more medical groups, 4 group practices and clinics and 2 clinical labs, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alperovich practices, 8 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Alperovich's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Alperovich is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Alperovich's licenses on file in 2 states: New York and Michigan.

Dmand AI lists chronic anemia among the conditions Dr. Alperovich treats.

CMS data shows 148 Medicare services from Dr. Alperovich across 1 procedure code in 2024, for 43 Medicare patients. Medicare paid $15,227 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 43 Medicare patients who saw Dr. Alperovich in 2024. The largest group is 65 to 74, with 22 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 35% are also on Medicaid. Their average risk score is 4.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alperovich's median patient age at 70, with 45% women.

In 2024, Dr. Alperovich wrote 14 Medicare Part D claims. 79% of them were for generic drugs. They cover 1 drug, with $273 in total drug cost. In 2022, CMS named 50 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Alperovich for performance year 2024, reported through an alternative payment model (APM). Dr. Alperovich accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 14 papers to Dr. Alperovich, published from 2015 to 2022. 2020 was the busiest year, with 5. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Follicular and Lymphoma, Large B-Cell, Diffuse. Dr. Alperovich has published most often in Blood Cancer J. Dr. Alperovich's most frequent co-authors are Connie Wing-Ching Lee Batlevi, MD, PhD, Anas Younes, MD and Andrew D. Zelenetz, MD.

CMS Open Payments shows 56 general payments to Dr. Alperovich from 24 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 59% of the total. Sanofi and Genzyme US Companies paid the most, $5,507.

Dr. Alperovich graduated from St. George's University School of Medicine in 2012.

Dr. Alperovich is in network with 14 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.